Home
 /
Papers
 /
Biochemistry
 /
Small molecule inhibitors of the NorA multidrug efflux pump potentiate antibiotic activity by binding the outward-open conformation
Preprint
Open access
Top 1% · Validated by QED

Small molecule inhibitors of the NorA multidrug efflux pump potentiate antibiotic activity by binding the outward-open…

Janine L. Gray, Elizabeth V. K. Ledger, Tiffany Suwatthee +16 more
August 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.08.19.671038
99
%
QED Score
QED Impressions

By revealing a novel binding site that locks NorA outward-open and demonstrating in vivo efficacy in MRSA infection, this work transforms efflux pump inhibition from a long-stalled concept into a structurally validated antibiotic adjuvant strategy.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

IMP-2380, a novel small molecule inhibitor discovered through phenotypic screening, potentiates ciprofloxacin activity against MRSA by binding to the NorA multidrug efflux pump in its outward-open conformation with nanomolar potency, thereby preventing antibiotic efflux, suppressing SOS response activation, blocking resistance emergence, and demonstrating efficacy in a murine infection model as the first structurally-characterized, in vivo-active NorA inhibitor.

See full analysis
Main Claim 1 –

HTS Identifies Compound 1 Inhibiting SOS and Potentiating Ciprofloxacin

Supporting evidence

  • SOS Inhibitors Selectively Potentiate Fluoroquinolones, Not Other Antibiotics
  • Compound 1 and IMP-2380 Lack Cytotoxicity and Intrinsic Antibacterial Activity
  • SAR Optimization Produces IMP-2380 with 10-Fold Higher Potency
Main Claim 2 –

Transposon Screens Identify NorA as Target of IMP-2380

Supporting evidence

  • IMP-2380 Inhibits NorA Efflux with >400-Fold Improved Potency
  • NorA Inhibitors Act Only in NorA-Containing Bacterial Species
  • NorA Inhibition Suppresses SOS Activation and Prophage Induction
  • NorA Inhibition Blocks Ciprofloxacin Resistance Emergence via Multiple Pathways
Main Claim 3 –

IMP-2380 Locks NorA in Outward-Open Conformation

Supporting evidence

  • Analog SAR Matches NorA–IMP-2380 Structure-Derived Binding Interactions
Main Claim 4 –

IMP-2380 Plus Ciprofloxacin Reduces MRSA Burden In Vivo

Supporting evidence

  • IMP-2380 Pharmacokinetics Enable In Vivo Exposure Despite High Binding

Abstract

Antibiotic resistance is among the greatest threats of the modern era. Multidrug efflux pumps expel antibiotics from bacterial cells and present a particular challenge by conferring resistance to a broad range of antibiotic classes; however, there is currently a lack of potent and selective inhibitors. Here, we report the discovery of IMP-2380, a drug-like chemical probe for the multidrug efflux pump NorA that delivers low-nanomolar potentiation of ciprofloxacin activity in vitro and activity in an in vivo S. aureus infection model. A phenotypic high-throughput screen for inhibitors of the ciprofloxacin-activated SOS DNA repair pathway in methicillin-resistant Staphylococcus aureus (MRSA) identified hit compounds targeting NorA, and subsequent optimization established IMP-2380 as the most potent NorA inhibitor discovered to date. The structure of NorA bound to IMP-2380 was solved by cryo-electron microscopy at 2.52 Å resolution, revealing that the small molecule locks the pump in the ‘outward-open’ conformation. This closes the inner face and prevents antibiotics binding from the cytosol, providing an explanation for the exceptional potency of IMP-2380 and structure-activity relationship across the series. IMP-2380 represents an in vivo active NorA inhibitor, functioning via a structurally defined outward-open binding mode, and will enable future exploration of NorA as a druggable target to combat antibiotic resistance.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?